Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17925/EE.2018.14supp1.2 http://scihub22266oqcxt.onion/10.17925/EE.2018.14supp1.2 C6009413!6009413 !30034546     free     free     free       Eur+Endocrinol 2018 ; 14 (Suppl1 ): 2-9 Nephropedia Template TP {{tp|p=30034546 |t=2018. Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons |pdf=|usr=}}{{30034546 }} gab.com Text Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons JO: Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=30034546 #FOAvip Insulin analogues play a key role in the effective management of type 2 diabetes. However, there are several behavioural barriers to appropriate early initiation of insulin therapy, despite compelling evidence supporting the benefits of this strategy in those patients for whom oral anti-diabetes agents provide insufficient control. The development of second-generation insulin analogues (insulin glargine 300 U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. These characteristics may help overcome patient and physician concerns about early insulin use in disease management. To date, there have been no head-to-head comparisons of second-generation insulins: here we consider recent real-world evidence and the forthcoming direct comparison in the BRIGHT randomised controlled study, as presented at the recent 11(th) International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2018. Twit Text FOAVip Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons ????Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=30034546 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30034546 #FOAvip English Wikipedia <ref>{{Cite pmid|30034546 }}</ref> Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons #MMPMID30034546 Mauricio D ; Hramiak I Eur Endocrinol 2018[May]; 14 (Suppl1 ): 2-9 PMID30034546 show ga Insulin analogues play a key role in the effective management of type 2 diabetes. However, there are several behavioural barriers to appropriate early initiation of insulin therapy, despite compelling evidence supporting the benefits of this strategy in those patients for whom oral anti-diabetes agents provide insufficient control. The development of second-generation insulin analogues (insulin glargine 300 U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. These characteristics may help overcome patient and physician concerns about early insulin use in disease management. To date, there have been no head-to-head comparisons of second-generation insulins: here we consider recent real-world evidence and the forthcoming direct comparison in the BRIGHT randomised controlled study, as presented at the recent 11(th) International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2018. ?Second-Generation Insulin Analogues - a Review of Recent Real-World Da(epmc).pdf DeepDyve Pubget Overpricing